| CYTOMX THERAPEUTICS INC. |
| USA |
| Gesundheit |
| US23284F1057 / A14158 |
| 6C1 (Frankfurt) / CTMX (NASDAQ) |
| FRA:6C1, ETR:6C1, 6C1:GR, NASDAQ:CTMX |
| - |
| https://cytomx.com/ |
|
CytomX Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative drug therapies aimed primarily at oncology. The company's core mission is to redefi..
>Volltext.. |
| 694.56 Mio. EUR |
| 575.96 Mio. EUR |
| 99.53 Mio. EUR |
| 21.39 Mio. EUR |
| 24.54 Mio. EUR |
| 0.37 EUR |
| 4.9 Mio. EUR |
| 29.94 Mio. EUR |
| -63.29 Mio. EUR |
| 3.5 |
| -14.85% |
| 92.22% |
| - |
| - |
| - |
| - |
| CYTOMX |
| 16.03.26 |
|